A panel missing PSA and LH sends you back to the lab.
Built to AUA Table 7. Two morning draws at intake, because the guideline requires two. IGF-1 monitoring for the secretagogues you already dispense. And 80+ peptides at clinic pricing, with no incumbent supplier to displace.
Clinic pricing on the panel. Clinic pricing, Net 30 on the peptide line.
TRT Baseline panel, proposed pricing. Positioned against Labcorp’s $219 men’s health panel — broader, and guideline-complete where theirs is not.
The re-test is the guideline, not the upsell.
Men’s health is the best-shaped channel in our catalogue: cash-pay membership, no insurance friction, and a buyer whose repeat testing is clinically compelled rather than sales-generated.
AUA Strong Recommendation, Grade A: low testosterone cannot be diagnosed without two separate early-morning measurements. Every new patient is a two-panel event at intake.
Baseline workup, a 3–6 month check, then a 12-month check. Steady state is 1–2 a year, every one of them guideline-driven.
TRT Nation $99 · Premier Health $99–119 · Hone Health $135–155. Your buyer already sells recurring cash-pay services.
No guideline requires quarterly labs. Many clinics test every 90 days as a retention practice — that is a business convention, not AUA or Endocrine Society guidance, and we will not print it as one. AUA Testosterone Deficiency Guideline, Table 7 (2018, validity confirmed 2024); Endocrine Society CPG 2018, PMID 29562364.
Everything AUA Table 7 asks for.
One morning fasting draw, run twice at intake. The analytes in orange are the six we added to the General Wellness panel to make it guideline-complete — without them a clinic orders a second panel anyway, which destroys the reason to switch suppliers.
Hormone axis
- Total testosteroneLC-MS/MS · two morning draws
- SHBGunlocks calculated free T
- Free testosteronecalculated from total T, SHBG, albumin
- LHprimary vs secondary — the treatment fork
- FSHfertility-interested men
- Prolactinreflexed on low or low-normal LH
- Estradiolsensitive LC-MS/MS
Safety & metabolic
- CBC with differentialhematocrit — the monitored risk
- PSArequired over 40 before starting
- Comprehensive metabolic panelincludes the albumin free-T needs
- Lipid panelcardiovascular context
- IGF-1response marker for GH secretagogues
- TSHthyroid alters SHBG and mimics symptoms
Hematocrit is already covered by the CBC — AUA requires it at baseline and every 6–12 months, holding therapy above 54%. The comprehensive metabolic panel already carries the albumin that calculated free testosterone needs, so SHBG alone unlocks it. Cortisol and DHEA appear in the wider General Wellness panel and are not part of AUA or Endocrine Society TRT monitoring; they support a vitality narrative and we sell them as that, not as guideline-required testing.
What this panel is not.
Your medical director will ask these before they ask about price. We would rather answer them on the page.
What it does
- Completes an AUA workup. Total T, LH, FSH, prolactin, SHBG, free T, PSA and hematocrit — the full decision set in one draw.
- Supports the treatment fork. LH is what separates primary from secondary hypogonadism, and therefore TRT from hCG or a SERM.
- Monitors the peptides you dispense. IGF-1 is the correct response and safety marker for GH secretagogues.
What it does not do
- It does not diagnose on one draw. AUA requires two separate early-morning measurements, same lab, same assay. We price and package it that way.
- It is not cheaper than your current lab. It is broader. Labcorp’s testosterone panel is $159. We do not pitch on price.
- It does not replace your lab account. For patients mid-course on another assay, AUA says stay on that assay. This is for new starts.
Weight loss raises testosterone.
This is the strongest evidence in our entire catalogue, and it is the claim that turns a weight-management patient into a TRT patient — or keeps one off therapy altogether.
Roughly 138 ng/dL, across 44 studies and 1,774 men after weight loss.
Of obesity-associated secondary hypogonadism after substantial weight loss.
In the same direction and magnitude, in the incretin subgroup specifically.
Obesity lowers total testosterone through aromatisation and SHBG suppression, and weight loss reverses part of it. That is a mechanism and a measured effect — not a claim that a GLP-1 treats hypogonadism, and we will not let it be sold as one.
The one loop Quest and Labcorp cannot copy.
Your reference laboratory sells you the marker. It does not sell you the compound the marker monitors. We sell both.
You dispense the secretagogue
Ipamorelin, CJC-1295 + Ipamorelin, Sermorelin or Tesamorelin, at clinic pricing with no incumbent supplier to displace.
Clinic pricingIGF-1 measures the response
IGF-1 is the correct response and safety marker for GH secretagogues — and it is already in the panel.
Already in the panelThe re-test is clinically indicated
Dose titration needs a number. That is a second panel your patient needs, not one you have to sell.
Not a sales eventThe only controlled trial of growth hormone combined with testosterone reported carpal tunnel in 32% of men versus 0% on placebo, arthralgias in 41% versus 0%, and more glucose intolerance. Testosterone amplifies the GH/IGF-1 axis, so a dose that is benign alone can push IGF-1 supraphysiologic on TRT. That is exactly why IGF-1 belongs in the panel — and why we will not market secretagogues as risk-free. Blackman et al., JAMA 2002 · doi 10.1001/jama.288.18.2282.
80+ compounds, graded on the evidence in this population.
Compounded by MicroAmino — a stated purity of ≥99% with a COA every batch. We grade the categories rather than sell them all at the same volume.
| Category | Compounds | Evidence in this population |
|---|---|---|
| GLP-1 & metabolic | Semaglutide · Tirzepatide · Cagrilintide · AOD-9604 | Strong |
| Growth hormone | Ipamorelin · CJC-1295 · Sermorelin · Tesamorelin | Moderate |
| Fertility / HPG axis | HCG · Gonadorelin · Kisspeptin | Moderate |
| Longevity | NAD+ · Epitalon · SS-31 · MOTS-C · Glutathione | Moderate |
| Healing & recovery | BPC-157 · TB-500 · GHK-Cu · KPV · Thymosin Alpha-1 | Moderate |
| Sexual health | PT-141 · Oxytocin | Caution |
IGF-1 LR3 — no approval, no human trial, and IGF-I associates with prostate cancer at OR 1.29 in the largest pooled analysis, which is the wrong biomarker to raise in men on androgens. And the P/V shot and sexual-rejuvenation exosome lines — the decisive blinded US trial of the comparable injection was flatly negative, 58.3% versus 53.6%, p=0.73. PT-141 is marked CAUTION because it is approved only for premenopausal women and is contraindicated in uncontrolled hypertension, which is this population’s comorbidity profile.
Peptide economics
You buy at clinic pricing and set your own retail. Patient prices below are modelled at 3× clinic cost for illustration only.
| Product | Category | Clinic price | Patient (3×) | Your margin |
|---|---|---|---|---|
| CJC-1295 + Ipamorelin 5+5 mg | Growth hormone | $46 | $138 | $92 |
| Ipamorelin 10 mg | Growth hormone | $58 | $174 | $116 |
| Tesamorelin 10 mg | Growth hormone | $60 | $180 | $120 |
| Sermorelin 10 mg | Growth hormone | $70 | $210 | $140 |
| Tirzepatide 30 mg | GLP-1 & metabolic | $195 | $585 | $390 |
| NAD+ 1000 mg | Longevity | $97 | $291 | $194 |
| Thymosin Alpha-1 5 mg | Healing & recovery | $46 | $138 | $92 |
| BPC-157 + TB-500 10+10 mg | Healing & recovery | $67 | $201 | $134 |
Highlighted are the four lines the IGF-1 loop runs on. At 3× your margin is 67%. Minimums are 20 units per product on vials and 10 on pens, Net 30. Supplied to licensed healthcare providers only, on a physician’s order.
Three panels per new patient in year one.
Two to diagnose, because AUA requires two. One to monitor. Then one to two a year thereafter on the existing panel.
| New patients per month | Panels / month | You keep each | Monthly | Annual |
|---|---|---|---|---|
| 10 new starts | 30 | $100 | $3,000 | $36,000 |
| 20 new starts | 60 | $100 | $6,000 | $72,000 |
| 40 new starts | 120 | $100 | $12,000 | $144,000 |
Buy ten or more of any SKU and we match it. Peptide margin is on top of this and is bought on the same terms. Illustrative, and not a guarantee of results.
Six questions, six straight answers
We have pre-written the hard ones, including the three where the honest answer is not in our favour.
What is the turnaround?
A local patient service centre returns results in one to three business days. A kit adds shipping both ways. We commit to a measured number in writing or we do not raise it.
Is the laboratory CLIA-certified?
Yes, and we provide the certificate number before you order. TRT titration is a diagnostic act — if we could not answer this, there would be no conversation.
Does it come into my EMR?
Not as discrete values today. You get a PDF, which means manual entry — roughly three to five minutes per result. That is a real cost and we are not going to pretend otherwise.
This is more than my current lab.
It is. It is broader, and it is a retail product you mark up rather than a cost line. We do not pitch on price and you should not buy on it.
Should I keep existing patients on their assay?
You should. AUA says measure at the same laboratory on the same assay over time. This is for new starts, and moving a stable patient mid-course is worse care for a smaller reason.
Why not just add IGF-1 to my current panel?
You can. But your laboratory does not sell the secretagogue that IGF-1 monitors, and we do — at clinic pricing, with no incumbent supplier to displace.
What it takes to run it.
Four questions decide whether this works in a clinic your size.
Who orders the test?
You do. It is your patient, your workup and your prescribing decision. We supply the kit, the laboratory and the report — we do not insert a telehealth physician between you and your patient.
How is the sample collected?
Morning fasting draw, in your clinic. AUA requires early-morning collection, which is precisely why this is a clinic-administered panel and not a mail-in kit.
How much staff time?
The draw you already do, plus packaging and dispatch. The added cost is manual result entry — call it three to five minutes per panel until we have an interface.
What does it cost to start?
Nothing on the panel. Your opening order, training and portal access. You pay for The peptide line is a normal opening order at clinic pricing.
Three things we put in writing first.
Each of these can end the conversation on its own. We would rather resolve them before you commit than after.
CLIA certificate and accreditation
The certificate number and accreditation status of the performing laboratory. You cannot dose from a result you cannot stand behind, and neither can we.
Assay methods, named
Testosterone by LC-MS/MS, estradiol by sensitive LC-MS/MS. Direct immunoassay estradiol is unreliable at male concentrations and we will not sell it as a monitoring feature.
Turnaround, measured to you
Not a category average — the actual round trip to your address, measured and committed in the agreement.
Why we lead with this: a men’s health clinic titrating testosterone is making a diagnostic decision on every result. A vendor who cannot name their laboratory, their assay and their turnaround is asking you to take that risk on trust. We would rather earn it on paper.
Land on peptides. Attach the panel.
The fastest path in is not the panel — it is the compound your laboratory cannot sell you. Start there, attach IGF-1 monitoring, then move the baseline panel onto new starts.
Open on peptides
Register, verify, and place an opening order on the growth-hormone line. No incumbent supplier to displace and no switching cost.
Clinic pricing, Net 30Attach IGF-1
Add IGF-1 monitoring to the patients already on secretagogues. This is the loop your reference laboratory structurally cannot offer.
The differentiatorMove new starts to the panel
Existing patients stay on their current assay, per AUA. New intakes move to the two-draw baseline.
New starts onlyWhat we send before you order
- The performing laboratory’s CLIA certificate number
- Named assay methods for testosterone and estradiol
- Turnaround measured to your practice address
- The peptide price sheet and titration schedules
- The clinic-side price for the TRT Baseline panel
Panels are laboratory-developed tests performed by a CLIA-certified laboratory. They are not FDA-cleared for the indications described and do not diagnose disease; diagnosis of testosterone deficiency requires two early-morning measurements per AUA guidance. Peptide products are supplied to licensed healthcare providers only.